Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03190174 · OUTCOME

Overall Survival

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers · Source last updated 2025-02-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
30 weeks

What was measured

The overall survival is the time from treatment initiation to death.

Analysis population: Per pre-specified analysis, only participants in the expansion phase of the study were evaluated.

Groups in this outcome

Expansion Phase 1b

Following dose escalation, an additional 25 patients will receive ABI-009 at the MTD and defined doses of nivolumab to assess overall safety and potential efficacy in a greater number of patients. Patients in the expansion phase of the study may continue treatment up to 18 three-week cycles or until significant disease progression or unacceptable toxicity occurs.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Expansion Phase 1b25

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Expansion Phase 1b22Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        22
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
The overall survival is the time from treatment initiation to death.
groups
  1. description
    Following dose escalation, an additional 25 patients will receive ABI-009 at the MTD and defined doses of nivolumab to assess overall safety and potential efficacy in a greater number of patients. Patients in the expansion phase of the study may continue treatment up to 18 three-week cycles or until significant disease progression or unacceptable toxicity occurs.
    id
    OG000
    title
    Expansion Phase 1b
param Type
COUNT_OF_PARTICIPANTS
population Description
Per pre-specified analysis, only participants in the expansion phase of the study were evaluated.
reporting Status
POSTED
time Frame
30 weeks
title
Overall Survival
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice